The VC fund is setting up the venture with its CSO, David Grainger, Ph.D., and Johnson & Johnson’s Richard Mason. 

The new funding will propel Unity Biotechnologies' osteoarthritis asset into its first clinical trial.

ShangPharma Innovation is growing its life science incubator on the West Coast as it looks to help early-stage biomedical work get off the ground.

Artificial intelligence company twoXAR says first-round financing will also help it build its pipeline and recruit new staff.

Arbor Biotechnologies has emerged from the shadows with $15.6 million in funding and a CRISPR enzyme that targets RNA.

Ideaya expects to get its first synthetic lethality and immuno-oncology assets into human testing in the first half of next year.

Foghorn seeks to unravel chromatin regulation and develop drugs to correct problems with it.

Perceptive leads a Series B round that will fund Crinetics' CRN00808 candidate through proof-of-concept studies.